Axon Stock Slumps on Dilution Fears After $1 Billion Notes Plan
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Already have an account? Sign in.
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Ongoing Operations Adjusted EBITDA rose over 50% to $2.38B; 2026 guidance was raised and a $1.5B buyback boost was announced.
Moderna lifted its 2026 revenue growth forecast to 15–25% after strong international COVID vaccine sales helped it return to profit in Q3.
Lilly partners with Hims & Hers so patients can access Zepbound ($299/mo) and Foundayo ($149/mo) at self-pay prices on the telehealth platform.
Be the first to know when deals break, stocks move, or biotech headlines hit.